In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 5, 1998, Pages 1057-1061

  Ryder, Neil S ^a   Wagner, Sonja ^a   Leitner, Ingrid ^a  

^a NOVARTIS RESEARCH INSTITUTE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MUCOCUTANEOUS CANDIDIASIS; PRIORITY JOURNAL; SKIN CULTURE;

EID: 0031970339     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.5.1057     Document Type: Article

References (37)

1. Alexander, B. D., and J. R. Perfect. 1997. Antifungal resistance trends towards the year 2000 - implications for therapy and new approaches. Drugs 54:657-678.
2. Balfour, J. A., and D. Faulds. 1992. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 43:259-284.
3. Clayton, Y. M. 1994. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br. J. Dermatol. 130(Suppl. 43.):7-8.
4. Evans, E. G. V. 1997. The clinical efficacy of terbinafine in the treatment of fungal infections of the skin. Rev. Contemp. Pharmacother. 8:325-341.
5. Faergemann, J., H. Zehender, J. Denouel, and L. Millerioux. 1993. Levels of terbinafine in plasma, stratum-corneum, dermis-epidermis (without stratum-corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for 4 weeks. Acta Dermato-Venereol. 73:305-309.
6. Girmenia, C., P. Martino, F. De Bernardis, G. Gentile, M. Boccanera, M. Monaco, G. Antonucci, and A. Cassone. 1996. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin. Infect. Dis. 23:506-514.
7. Hiratani, T., Y. Asagi, and H. Yamaguchi. 1991. Evaluation of in vitro antimycotic activity of terbinafine, a new allylamine agent. Jpn. J. Med. Mycol. 32:323-332.
8. Jones, T. C. 1990. Treatment of dermatomycoses with topically applied allylamines: naftifine and terbinafine. J. Dermatol. Treat. 1(Suppl. 2):29-32.
9. Jung, E. G., P. J. Haas, M. Brautigam, and G. Weidinger. 1994. Systemic treatment of skin candidosis: a randomized comparison of terbinafine and ketoconazole. Mycoses 37:361-365.
10. Kagawa, S. 1989. Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis. Clin. Exp. Dermatol. 14:114-115.
11. Kolaczkowski, M., and A. Goffeau. 1997. Active efflux by multidrug transporters as one of the strategies to evade chemotherapy and novel practical implications of yeast pleiotropic drug resistance. Pharmacol. Ther. 76:219-242.
12. Law, D., C. B. Moore, L. A. Joseph, M. G. L. Keaney, and D. W. Denning. 1996. High incidence of antifungal drug resistance in Candida tropicalis. Int. J. Antimicrob. Agents 7:241-245.
13. Marichal, P., J. Gorrens, M. C. Coene, L. Le Jeune, and H. Vanden Bossche. 1995. Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Mycoses 38:111-117.
14. McGinley, K. J., E. L. Larson, and J. J. Leyden. 1988. Composition and density of microflora in the subungual space of the hand. J. Clin. Microbiol. 26:950-953.
15. Nandwani, R., A. Parnell, M. Youle, C. J. N. Lacey, E. G. V. Evans, J. Midgley, J. Cartledge, and D. A. Hawkins. 1996. Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis. Br. J. Dermatol. 134(Suppl. 46):22-24.
16. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards. Wayne, Pa.
17. Nolting, S., M. Brautigam, and G. Weidinger. 1994. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br. J. Dermatol. 130(Suppl. 43):16-21.
18. Odds, F. C. 1994. Pathogenesis of Candida infections. J. Am. Acad. Dermatol. 31(Suppl.):S2-S5.
19. Petranyi, G., J. G. Meingassner, and H. Mieth. 1987. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob. Agents Chemother. 31:1365-1368.
20. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
21. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
22. Ryder, N. S. 1985. Specific inhibition of fungal sterol biosynthesis by SF 86-327. a new allylamine antimycotic agent. Antimicrob. Agents Chemother. 27:252-256.
23. Ryder, N. S. 1992. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br. J. Dermatol. 126(Suppl. 39):2-7.
24. Ryder, N. S., and M.-C. Dupont. 1985. Inhibition of squalene epoxidase by allylamine antimycotic compounds: a comparative study of the fungal and mammalian enzymes. Biochem. J. 230:765-770.
25. Ryder, N. S., and B. Favre. 1997. Antifungal activity and mechanism of action of terbinafine. Rev. Contemp. Pharmacother. 8:275-287.
26. Ryder, N. S., and H. Mieth. 1992. Allylamine antifungal drugs. Curr. Top. Med. Mycol. 4:158-188.
27. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1995. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40:2300-2305.
28. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143:405-416.
29. Sanz-Asenjo, A., J. A. Heras-Tabernero, S. Vidal-Asensi, and C. Arjona-Manuel. 1997. Healing of a multidrug resistant cutaneous cryptococcosis with oral terbinafine. Australas. J. Dermatol. 38(Suppl. 2):120.
30. Schatz, F., M. Brautigam, E. Dobrowolski, I. Effendy, H. Haberl, H. Mensing, G. Weidinger, and A. Stuetz. 1995. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin. Exp. Dermatol. 20:377-383.
31. Schaude, M., H. Ackerbauer, and H. Mieth. 1987. Inhibitory effect of antifungal agents on germ tube formation in Candida albicans. Mykosen 30:281-287.
32. Segal, R., A. Kritzman, L. Cividalli, Z. Samra, and M. David. 1996. Treatment of Candida nail infection with terbinafine. J. Am. Acad. Dermatol. 35:958-961.
33. Shadomy, S., A. Espinell-Ingroff, and R. J. Gebhart. 1985. In vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia 23:125-132.
34. Villars, V., and T. C. Jones. 1990. Present status of the efficacy and tolerability of terbinafine (Lamisil) used systemically in the treatment of dermatomycoses of skin and nails. J. Dermatol. Treat. 1(Suppl. 2):33-38.
35. Villars, V. V., and T. C. Jones. 1992. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br. J. Dermatol. 129(Suppl. 39):61-69.
36. Weems, J. J. 1992. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin. Infect. Dis. 14:756-766.
37. Zaias, N. 1997. Candida: a review of clinical experience with Lamisil(R). Dermatology 194(Suppl. 1):10-13.